Response and Survival
PD
DISEASE
The best responses for patients in Arm A (carboplatin/paclitaxel plus ipatasertib) included 2 (20%) PR (for the RP2D it was 2/7, 29%), 4 (40%) SD, and 4 (40%) PD. Arm B (carboplatin plus ipatasertib) best response included 1 (8%) CR, 2 (17%) PR, 6 (50%) SD, and 3 (25%) PD. Arm C (capecitabine, atezolizumab, and plus ipatasertib) best response included 2 (33%) PR, 3 (50%) SD, and 1 (17%) was called progressive disease, but we noted the patient was HER2+ on biopsy of progressive disease (Response per RECIST 1.1 (


The median PFS for Arm A was 4.8 months (95% CI 2.8, NA), Arm B was 3.9 months (95% CI 2.8, NA), and Arm C was 8.2 months (95% CI 4.6, NA). The median OS for Arm A (Progression-free survival (PFS) and overall survival (OS) (A swimmer plot with response to treatment over time is shown for Arm A (Swimmer plot (